12.02
+0.28(+2.39%)
Currency In USD
| Previous Close | 11.74 |
| Open | 11.75 |
| Day High | 12.34 |
| Day Low | 11.67 |
| 52-Week High | 28.25 |
| 52-Week Low | 5.9 |
| Volume | 5.34M |
| Average Volume | 6.77M |
| Market Cap | 1.26B |
| PE | -2.83 |
| EPS | -4.25 |
| Moving Average 50 Days | 9.61 |
| Moving Average 200 Days | 11.38 |
| Change | 0.28 |
If you invested $1000 in Intellia Therapeutics, Inc. (NTLA) since IPO date, it would be worth $543.89 as of January 14, 2026 at a share price of $12.02. Whereas If you bought $1000 worth of Intellia Therapeutics, Inc. (NTLA) shares 5 years ago, it would be worth $144.3 as of January 14, 2026 at a share price of $12.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 12:30 PM GMT
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will pres
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
GlobeNewswire Inc.
Nov 10, 2025 8:17 PM GMT
One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures of cardiomyopathy, regardless of NYHA Class, at 2
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
GlobeNewswire Inc.
Nov 08, 2025 10:13 PM GMT
Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free and long-term prophylaxis (LTP)-free 24 (75%) were attack-free and LTP-free for at least se